Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Debt to Equity (2016 - 2022)

Lexaria Bioscience's Debt to Equity history spans 8 years, with the latest figure at $0.0 for Q2 2022.

  • Quarterly results put Debt to Equity at $0.0 for Q2 2022, up 21.31% from a year ago — trailing twelve months through May 2022 was $0.0 (up 21.31% YoY), and the annual figure for FY2021 was $0.0, down 98.31%.
  • Debt to Equity for Q2 2022 was $0.0 at Lexaria Bioscience, up from $0.0 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.06 in Q4 2020 to a low of $0.0 in Q3 2021.
  • The 5-year median for Debt to Equity is $0.0 (2018), against an average of $0.01.
  • The sharpest move saw Debt to Equity tumbled 99.65% in 2018, then skyrocketed 2023.81% in 2021.
  • Year by year, Debt to Equity stood at $0.01 in 2018, then soared by 124.29% to $0.01 in 2019, then surged by 355.67% to $0.06 in 2020, then plummeted by 98.95% to $0.0 in 2021, then surged by 30.14% to $0.0 in 2022.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.0, $0.0, and $0.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.